Health Canada approves country's 1st generic version of Ozempic
The injectable semaglutide medication is manufactured by Dr. Reddy's Laboratories in India and is approved for the once-weekly treatment of Type 2 diabetes in adults.
globalnews.caHere’s a concise update on the latest about generic semaglutide in Canada.
Core answer
- Canada has approved generic versions of semaglutide for the first time in the G7, with Health Canada authorizing multiple generics in 2026 (including Dr. Reddy’s and Apotex), marking a major step in access to Ozempic/Wegovy’s active ingredient for type 2 diabetes treatment.[1][2][5]
Key developments
- First generic semaglutide approval: Health Canada granted approval for a Dr. Reddy’s version in late April 2026, confirming it meets safety, efficacy, and quality criteria for the once-weekly treatment of adults with type 2 diabetes.[1]
- Second generic approval: A second generic (Apotex) was approved shortly after, making Canada the first G7 country to authorize generic semaglutide and expanding the number of approved generics.[2][3]
- Market availability: By mid-May 2026, generic semaglutide was entering Canadian pharmacies, though regional supply may vary as products move through distribution channels.[4]
Context and impact
- Price and access: The introduction of generics is expected to lower costs relative to brand-name Ozempic/Wegovy, though the extent depends on the number of approved generics and market competition.[2][1]
- Regulatory oversight: Health Canada continues to monitor safety and effectiveness of all generic semaglutide products, with potential actions if safety concerns arise.[3]
Additional context
- Other submissions: Health Canada was reviewing several additional generic semaglutide submissions in 2026, indicating ongoing regulatory activity and potential further approvals.[3][2]
- Industry commentary: Analysts and obesity/diabetes care groups have commented on improved access but emphasize considerations for coverage and patient assistance as generics roll out.[9][10]
Would you like me to pull the most recent price guidance or patient access programs in Canada for these generics, or summarize regional availability by province? I can also provide a brief table comparing the two approved generics (Dr. Reddy’s vs Apotex) and their stated indications.
Citations
- Health Canada first generic semaglutide approval (Dr. Reddy’s)[5][1]
- Second generic approval (Apotex) and status as first G7 country[2][3]
- Pharmacy availability and supply considerations[4]
- Regulatory overview and ongoing reviews[3][2]
- Context from obesity/diabetes groups[10][9]